Funding to Expand Operational Capacity at Proteome Sciences
LONDON - Proteome Sciences plc, a contract proteomics service provider, has recently secured a loan agreement totaling £1 million. This agreement, in collaboration with Vulpes Investment Management Private Limited and Christopher Pearce, aims to effectively enhance the company's operational capabilities. With a strong focus on drug discovery, development, and biomarker identification, Proteome Sciences plans to utilize these funds to acquire a state-of-the-art Exploris mass spectrometer alongside providing additional working capital.
Positive Outlook for Growth amid Increased Order Demand
This loan facility, which operates as a revolving credit for a duration of two years, comes at a favorable time for Proteome Sciences, as the company has reported a significant increase in customer orders and service demand in the latter half of the year. This upward trend is forecasted to positively influence the company's revenue streams and overall business returns going forward.
Resilience in a Challenging Market
Even though the biotechnology sector posed challenges earlier in the year, as referenced in their recent Interim Results, Proteome Sciences has seen a strong uptick in orders, particularly for their TMTpro 35plex tags launched mid-year. The company has expressed confidence that this positive trajectory will extend into their work pipeline for 2025 and 2026, with the Board of Directors optimistic about significant revenue increases in the proteins and biomarker services segment.
Loan Details and Structure
The loan from Vulpes is classified as unsecured with a 10.0% per annum interest rate, while the loan from Christopher Pearce is secured against specific assets and intellectual property of the company, at an interest rate set at 2.5% above the Barclays (LON: BARC) Bank plc base rate. Both loans are due to be repaid on the second anniversary of the loan facility, with the company having the option to make partial repayments in increments of £100,000, provided they give a five-working-day notice.
Leadership Changes Following Financial Moves
In connection with this loan facility announcement, Proteome Sciences is also implementing significant changes within its directorate. Dr. Mariola Soehngen is set to leave her position at the close of January 2025. In the interim, Chairman Christopher Pearce will step into the role of Executive Chairman until a new CEO is appointed. Additionally, Chief Finance Officer Abdel Omari will resign as a director at the end of January but will continue to serve as a part-time financial consultant to the Board.
Independent Review of Loan Terms
The independent directors, following consultations with the company's nominated adviser Allenby Capital, have determined that the loan facility's terms are fair and reasonable from the shareholders' perspective. This information serves to keep shareholders informed about critical financial decisions and leadership transitions within Proteome Sciences.
Frequently Asked Questions
What is the purpose of the £1 million loan secured by Proteome Sciences?
The loan is intended to enhance operational capacity and fund the acquisition of a new Exploris mass spectrometer, alongside providing working capital.
Who are the lenders involved in this loan agreement?
The loan is provided by Vulpes Investment Management Private Limited and Christopher Pearce.
What has driven Proteome Sciences' increased orders recently?
The company has seen heightened demand for its TMTpro 35plex tags and overall services, particularly in the latter half of the year.
What changes are happening within Proteome Sciences’ leadership?
Dr. Mariola Soehngen will depart, with Chairman Christopher Pearce temporarily becoming Executive Chairman, and CFO Abdel Omari will also resign while continuing as a consultant.
How have shareholders been informed about the loan terms?
The independent directors, with the help of their adviser, assessed the loan terms and found them fair, and this information has been communicated to shareholders.
